

Liver Disease Treatments: The Global Market

Market Research Report | 2025-04-22 | 164 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

Report description:

Description

Report Scope:

This report on the global market for liver disease treatments provides qualitative and quantitative data on the current market dynamics. It discusses different liver diseases and their treatment modalities.

Analyses of the most frequently used products, clinical trials, new product approvals, and emerging technologies are also included. The demographics of the major regions-North America, Europe, Asia-Pacific, South America, and the Middle East and Africa-as well as their prospects for growth are summarized. The profiles of leading companies in the market and their strategies are also discussed.

The market for liver disease treatments is broken into hepatitis, non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma, autoimmune liver diseases, alcohol-induced liver disease (ALD), chronic liver disease, and others. The growth potential and forecast data are discussed for each disease for the aforementioned regions and many countries.

The report includes global revenue in \$ millions for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030.

Report Includes :

- 52 data tables and 63 additional tables
- Analyses of the trends in the global markets for liver disease treatments, with revenue data from 2023, estimates for 2024, forecasts for 2025, and projected CAGRs through 2029
- Estimates of the size and revenue prospects for the global market, along with a market share analysis by product (drug) type, disease type, route of administration, end user, and region
- Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

impacts of macroeconomic variables

- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- An assessment of the major drugs that can cause liver disease, the market's current situation and future prospects, clinical trials, new developments, and pipeline products
- An analysis of the key patent grants and recently published patents
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
- Analysis of the industry structure, including companies' product offerings, strategic alliances, M&A activity, venture fundings and investment outlook
- Company profiles of major players within the industry, including Gilead Sciences Inc., Bristol Myers Squibb Co., AbbVie Inc., and Merck & Co. Inc.

Executive Summary

Summary:

The global market for liver disease treatments is estimated to increase from \$46.0 billion in 2024 to reach \$69.1 billion by 2030, at a compound annual growth rate (CAGR) of 7.1% from 2025 through 2030.

Liver diseases, which include cirrhosis, viral hepatitis and liver cancer, are responsible for more than 2 million deaths annually worldwide, or about 4% of all deaths (Devarbhavi H; et al.; Journal of Hepatology; 2023). An estimated 1 million people die each year from chronic liver disease and the cirrhosis it causes, and 600,000 to 900,000 die from liver cancer. Liver disease is the 11th most common cause of death worldwide, and the 15th most common cause of life years with a disability

The global market for liver disease treatments was valued at \$46.0 billion in 2024 and is expected to reach \$69.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.1% for the forecast period. Leading pharmaceutical companies in the liver disease treatment market include -

- Gilead Sciences: Known for its portfolio of hepatitis C treatments (e.g., Sovaldi, Harvoni) and ongoing work in non-alcoholic steatohepatitis (NASH) treatments.
- Bristol Myers Squibb: Active in the hepatitis market and liver cancer treatments with drugs like Opdivo and Yervoy.
- AbbVie: Its hepatitis C treatment, Mavyret, is one of the leading drugs on the market.
- Merck & Co.: Developing immunotherapies for liver cancer and also involved in hepatitis B treatments.

Biotechnology firms developing novel therapies for liver disorders, particularly those like liver fibrosis and NASH, are also showing interest in the market.

Table of Contents:

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Chapter 2 Market Overview

Overview

Classification of Therapies, by Disease and Product

Hepatitis

Liver Tumors and Liver Cancer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Autoimmune Liver Diseases
Alcohol-induced liver disease
Chronic Liver Disease
Non-Alcoholic Fatty Liver Disease
Analysis of Macroeconomic Factors
Population Demographics and Aging Population
Global Economic Growth
Geopolitical Risks, Trade Wars, and Supply Chain Disruptions
Public Awareness and Education
Porter's Five Forces
Potential for New Entrants (Moderate to Low)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (Moderate to High)
Threat of Substitute Products or Services (Low to Moderate)
Industry Competitiveness (High)
Chapter 3 Market Dynamics
Overview
Market Drivers
Increasing Incidence of Liver Diseases
Consumption of Alcohol and Improper Diet
Government Initiatives to Provide Vaccines and Grow Awareness
Market Restraints
FDA Approvals and Stringent Government Regulations
Side Effects and Risks Associated with Drugs
Market Opportunities
Advances in Treatment Options
Emerging Markets and Access to Treatment
Chapter 4 Regulatory Landscape
Global Regulatory Agencies
U.S. Food and Drug Administration
European Medicines Agency
Japan's Pharmaceuticals and Medical Devices Agency
China's National Medical Products Administration
Considerations in Liver Drug Development
Chapter 5 Emerging Trends and Pipeline Analysis
Emerging Trends
Personalized Medicine in Liver Disease
Advances in Liver Transplantation
Regenerative Medicine and Stem Cell Therapy
Immunotherapy for Liver Cancer
Repairing Liver Disease with mRNA
Pipeline Analysis
Patent Analysis
Findings
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Breakdown, by Disease Type

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Takeaways
Hepatitis
Non-Alcoholic Fatty Liver Disease
Hepatocellular Carcinoma
Autoimmune Liver Diseases
Alcohol-induced Liver Disease (ALD)
Chronic Liver Disease
Other Liver-Related Diseases
Geographic Breakdown
Market Breakdown, by Region
Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Chapter 7 Competitive Intelligence
Takeaways
Market Ranking of Leading Companies
Strategic Analysis
Venture Funding and Investments
Chapter 8 Sustainability in the Liver Disease Treatment Industry: ESG Perspective
Overview
Environmental Sustainability
Social Responsibility (S)
Governance
ESG Risk Ratings
Concluding Remarks from BCC
Chapter 9 Appendix
Research Methodology
Sources
Abbreviations
Company Profiles
ABBVIE INC.
ASTRAZENECA
BAYER AG
BIOTEST AG
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC.
INTERCEPT PHARMACEUTICALS INC.
MADRIGAL PHARMACEUTICALS
MERCK & CO. INC.
NOVARTIS AG
SALIX PHARMACEUTICALS
SANOFI

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Liver Disease Treatments: The Global Market

Market Research Report | 2025-04-22 | 164 pages | BCC Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-13"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com